1. Home
  2. JKHY vs IMVT Comparison

JKHY vs IMVT Comparison

Compare JKHY & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jack Henry & Associates Inc.

JKHY

Jack Henry & Associates Inc.

HOLD

Current Price

$150.13

Market Cap

9.7B

Sector

Technology

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$39.19

Market Cap

8.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JKHY
IMVT
Founded
1976
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.7B
8.0B
IPO Year
2000
2019

Fundamental Metrics

Financial Performance
Metric
JKHY
IMVT
Price
$150.13
$39.19
Analyst Decision
Buy
Buy
Analyst Count
12
8
Target Price
$197.25
$33.00
AVG Volume (30 Days)
1.3M
1.1M
Earning Date
05-05-2026
05-28-2026
Dividend Yield
1.59%
N/A
EPS Growth
19.31
N/A
EPS
5.41
N/A
Revenue
$1,536,603,000.00
N/A
Revenue This Year
$8.03
N/A
Revenue Next Year
$6.39
N/A
P/E Ratio
$27.40
N/A
Revenue Growth
7.37
N/A
52 Week Low
$121.04
$14.32
52 Week High
$193.39
$41.23

Technical Indicators

Market Signals
Indicator
JKHY
IMVT
Relative Strength Index (RSI) 59.31 55.86
Support Level $146.92 $37.53
Resistance Level $157.87 $41.23
Average True Range (ATR) 4.46 1.48
MACD -0.13 -0.34
Stochastic Oscillator 57.92 41.08

Price Performance

Historical Comparison
JKHY
IMVT

About JKHY Jack Henry & Associates Inc.

Jack Henry is a leading provider of core processing and complementary services, including electronic funds transfer, payment processing, and loan processing, for US banks and credit unions, with a focus on small and midsize banks. Jack Henry serves almost 1,000 banks and over 700 credit unions.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.

Share on Social Networks: